New insights from ADVANCE

John Chalmers, Andre Pascal Kengne, Rohina Joshi, Vlado Perkovic, Anushka Patel

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)


Objectives ADVANCE (Action in Diabetes and Vascular Disease - PreterAx and DiamicroN MR Controlled Evaluation) is a large-scale clinical trial designed to investigate the benefits of blood pressure lowering and intensive glucose control in patients with type 2 diabetes mellitus. Conclusion The safety and efficacy of perindopril-indapamide in lowering blood pressure and of a gliclazide-MR-based regimen in lowering blood glucose have been established with the completion of a 6-week run-in phase and of more than 4 years of post-randomization follow-up. It is anticipated that ADVANCE will provide many new insights including: whether blood pressure lowering with perindopril-indapamide reduces the risk of both macrovascular and microvascular events irrespective of baseline blood pressure; whether more intensive blood pressure lowering with a gliclazide-MR-based regimen targeting on HbA1c levels of 6.5% or less reduces these two outcomes compared with standard guidelines therapy; and finally whether the separate benefits of these two treatment regimens are additive.

Original languageEnglish
Pages (from-to)S23-S30
JournalJournal of Hypertension
Issue numberSUPPL. 1
Publication statusPublished - Jun 2007
Externally publishedYes


  • Blood pressure lowering
  • Gliclazide-MR
  • Glucose control
  • Macrovascular disease
  • Microvascular disease
  • Perindopril-indapamide fixed dose combination
  • Type 2 diabetes mellitus


Dive into the research topics of 'New insights from ADVANCE'. Together they form a unique fingerprint.

Cite this